Annemieke S Littooij1, Neil J Sebire2, Øystein E Olsen3. 1. Department of Radiology and Nuclear Medicine, University Medical Center Utrecht/Wilhelmina Children's Hospital, Utrecht, the Netherlands. 2. Department of Pathology, Great Ormond Street Hospital for Children, London, UK. 3. Department of Radiology, Great Ormond Street Hospital for Children, London, UK.
Abstract
PURPOSE: To explore the potential relation between whole-tumor apparent diffusion coefficient (ADC) parameters in viable parts of tumor and histopathological findings in nephroblastoma. MATERIALS AND METHODS: Children (n = 52) with histopathologically proven nephroblastoma underwent diffusion-weighted magnetic resonance imaging (MRI) (1.5T) before preoperative chemotherapy. Of these, 25 underwent an additional MRI after preoperative chemotherapy, shortly before resection. An experienced reader performed the whole-tumor ADC measurements of all lesions, excluding nonenhancing areas. An experienced pathologist reviewed the postoperative specimens according to standard SIOP guidelines. Potential associations between ADC parameters and proportions of histological subtypes were assessed with Pearson's or Spearman's rank correlation coefficient depending on whether the parameters tested were normally distributed. In case the Mann-Whitney U-test revealed significantly different ADC values in a subtype tumor, this ADC parameter was used to derive a receiver operating characteristic (ROC) curve. RESULTS: The 25th percentile ADC at presentation was the best ADC metric correlated with proportion of blastema (Pearson's r = -0.303, P = 0.026). ADC after preoperative treatment showed moderate correlation with proportion stromal subtype at histopathology (r = 0.579, P = 0.002). By ROC analysis, the optimal threshold of median ADC for detecting stromal subtype was 1.362 × 10-3 mm2 /s with sensitivity and specificity of 100% (95% confidence interval [CI] 0.65-1.00) and 78.9% (95% CI 0.57-0.92), respectively. CONCLUSION: ADC markers in nephroblastoma are related to stromal subtype histopathology; however, identification of blastemal predominant tumors using whole-tumor ADC measurements is probably not feasible. LEVEL OF EVIDENCE: 3 J. MAGN. RESON. IMAGING 2017;45:1316-1324.
PURPOSE: To explore the potential relation between whole-tumor apparent diffusion coefficient (ADC) parameters in viable parts of tumor and histopathological findings in nephroblastoma. MATERIALS AND METHODS:Children (n = 52) with histopathologically proven nephroblastoma underwent diffusion-weighted magnetic resonance imaging (MRI) (1.5T) before preoperative chemotherapy. Of these, 25 underwent an additional MRI after preoperative chemotherapy, shortly before resection. An experienced reader performed the whole-tumor ADC measurements of all lesions, excluding nonenhancing areas. An experienced pathologist reviewed the postoperative specimens according to standard SIOP guidelines. Potential associations between ADC parameters and proportions of histological subtypes were assessed with Pearson's or Spearman's rank correlation coefficient depending on whether the parameters tested were normally distributed. In case the Mann-Whitney U-test revealed significantly different ADC values in a subtype tumor, this ADC parameter was used to derive a receiver operating characteristic (ROC) curve. RESULTS: The 25th percentile ADC at presentation was the best ADC metric correlated with proportion of blastema (Pearson's r = -0.303, P = 0.026). ADC after preoperative treatment showed moderate correlation with proportion stromal subtype at histopathology (r = 0.579, P = 0.002). By ROC analysis, the optimal threshold of median ADC for detecting stromal subtype was 1.362 × 10-3 mm2 /s with sensitivity and specificity of 100% (95% confidence interval [CI] 0.65-1.00) and 78.9% (95% CI 0.57-0.92), respectively. CONCLUSION: ADC markers in nephroblastoma are related to stromal subtype histopathology; however, identification of blastemal predominant tumors using whole-tumor ADC measurements is probably not feasible. LEVEL OF EVIDENCE: 3 J. MAGN. RESON. IMAGING 2017;45:1316-1324.
Authors: M Beatrice Damasio; Lil-Sofie Ording Müller; Thomas A Augdal; Fred E Avni; Luca Basso; Costanza Bruno; Damjana Ključevšek; Annemieke S Littooij; Stéphanie Franchi-Abella; Luisa M Lobo; Hans-Joachim Mentzel; Marcello Napolitano; Aikaterini Ntoulia; Michael Riccabona; Samuel Stafrace; M Magdalena M Woźniak; Philippe Petit Journal: Pediatr Radiol Date: 2019-11-27
Authors: Annemieke S Littooij; Peter G Nikkels; Christina A Hulsbergen-van de Kaa; Cees P van de Ven; Marry M van den Heuvel-Eibrink; Øystein E Olsen Journal: Pediatr Radiol Date: 2017-07-01
Authors: Justine N van der Beek; Janna A Hol; Aurore Coulomb-l'Hermine; Norbert Graf; Harm van Tinteren; Kathy Pritchard-Jones; Maite E Houwing; Ronald R de Krijger; Gordan M Vujanic; Kristina Dzhuma; Jens-Peter Schenk; Annemieke S Littooij; Gema L Ramírez-Villar; Dermot Murphy; Satyajit Ray; Reem Al-Saadi; Manfred Gessler; Jan Godzinski; Christian Ruebe; Paola Collini; Arnaud C Verschuur; Tony Frisk; Christian Vokuhl; Christina A Hulsbergen-van de Kaa; Beatriz de Camargo; Bengt Sandstedt; Barbara Selle; Godelieve A M Tytgat; Marry M van den Heuvel-Eibrink Journal: Int J Cancer Date: 2021-02-03 Impact factor: 7.396
Authors: Justine N van der Beek; Tom A Watson; Rutger A J Nievelstein; Hervé J Brisse; Carlo Morosi; Henrique M Lederman; Ana Coma; Maria M Gavra; Kristina Vult von Steyern; Karoly Lakatos; Luc Breysem; Edit Varga; Hubert Ducou Le Pointe; Maarten H Lequin; Jürgen F Schäfer; Hans-Joachim Mentzel; Andreas M Hötker; Giuseppina Calareso; Sophie Swinson; Martin Kyncl; Claudio Granata; Michael Aertsen; Pier Luigi Di Paolo; Ronald R de Krijger; Norbert Graf; Øystein E Olsen; Jens-Peter Schenk; Marry M van den Heuvel-Eibrink; Annemieke S Littooij Journal: J Magn Reson Imaging Date: 2021-08-06 Impact factor: 5.119